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ASCTMultiplemyeloma (MM) is a clonal B-cell malignancy characterized by aberrant expansion of plasma cellswithin
bone marrow and extramedullary sites. It is one of the most common haematological malignancies; it accounts
for 1.4% of all tumours and is responsible for 2% of cancer-related mortality. Over the last decades, the paradigm
of MM therapy has changed dramatically - from the conventional combination of oral melphatan+ prednisone,
high-dose chemotherapy with stem cell (ASCT) support for younger patients to the present paradigm with the
use of one (or more) of 3major new targeted agents - the ﬁrst-in class proteasome inhibitor bortezomib, the im-
munomodulatory drug thalidomide, and its more potent derivative lenalidomide. Their use as a part of initial
therapy is associated with high overall response rates as well as high rates of complete response (CR), both for
elderly patients unable to undergo ASCT and for younger patients treated prior to ASCT. Altogether, the advent
of novel agents has resulted in a 50% improvement in median survival. Moreover, the development of new
drug classes based on preclinical rationale and the introduction of next-generation agents are likely to further ex-
pand treatment options and improve outcomes for especially relapsedMM. This reviewhighlights important his-
toric landmarks as well as more recent events that have played an important role in the evolution of myeloma
targeted therapy.
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by aberrant expansion of plasma cells within bone marrow and, less
frequently, within extramedullary sites. It is one of the most common
hematological malignancies; it accounts for 1.4% of all tumors and is
responsible for 2% of cancer-related mortality. According to the results
of an extensive analysis based on data from across Europe, the USA
and Japan, the median survival of patients treated from 1981 to 2000
with high-dose therapy with autologous stem-cell transplantation
(ASCT) ranged from 5 to 7 years while, in contrast, it ranged from 3 to
5 years in elderly patients treated with conventional therapy [1].
Over the last three decades, the paradigm of MM therapy has
changed dramatically – from the conventional combination of oral
melphalan + prednisone and then high-dose chemotherapy with
stem cell (ASCT) support for younger patients to the present paradigm
with the use of one (or more) of 3 major new targeted agents – the
ﬁrst-in class proteasome inhibitor bortezomib, the immunomodulatoryehalf of the Research Network of Codrug thalidomide, and its more potent derivative lenalidomide. Their
use as a part of initial therapy is associated with high overall response
rates as well as high rates of complete response (CR), both for elderly
patients unable to undergo ASCT and for younger patients treated
prior to ASCT. Altogether, the advent of novel agents has resulted in a
50% improvement in median survival [2]. Moreover, the development
of new drug classes based on preclinical rationale and the introduction
of next-generation agents are likely to further expand treatment options
and improve outcomes for relapsed MM.
In terms of bortezomib, initial phase I/II and conﬁrmatory phase III
clinical trials were soon followed by its approval for the therapy of
refractory/relapsed multiple myeloma [3,4]. The potential use of combi-
nationswas suggested bynumerous preclinical studies; for example, sen-
sitization of myeloma cells derived from both melphalan-sensitive and
melphalan-resistant myeloma lines was observed when bortezomib
was added to melphalan [5,6]. In combined phase I and II studies,
bortezomib administered in combination with melphalan demonstrated
encouraging activity andmanageable toxicity in patientswith refractory/mputational and Structural Biotechnology. This is an open access article under the CC BY
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ing on the effect of the combination MP + bortezomib (MPV) in newly
diagnosed patients older than 65 years, resulting in 32% CR, a median
time to progression (TTP) of 27 months, and estimated overall survival
(OS) of 85% at 38 months [8]. These exciting results lead to the initiation
of the VISTA trial— amulticenter trial designed to compare the efﬁcacy of
MPV versusMP [9]. A randomized, open-label, phase 3 study,was carried
out in 151 centers across 22 countries. A total of 682 patients either older
than 65 years or younger not eligible for ASCT were enrolled. The per-
centages of partial responses (PR) or better were 71% vs. 35%,
respectively (P b 0.001), and CR rates were 30% vs. 4%, respectively
(P b 0.001). Median time to progression (the primary study endpoint)
was 24 months in the bortezomib-treated group, compared with
16.6 months in the control (P b 0.001). Median duration of response
in both groups was 19.9 vs. 13.1 months. This effect was especially
pronounced in patients who attained CR, with the median remission du-
ration in the bortezomib group of 24 months, compared to 12.8 months
for the control. Clinical beneﬁt was independent of age, sex, region, initial
beta-2 microglobulin, albumin, clinical stage according to International
Staging System (ISS) and creatinine clearance [10]. Results obtained
in patients with unfavorable cytogenetics (which is one of the main
negative prognostic factors in MM patients for all therapies used so far,
including ASCT) – t(4,14), t(4;16) translocations, 17p deletion, or 13q de-
letion –were comparable with those in the group without these, both in
terms of CR rates and in terms of similar TTP and OS. According to a
recent follow-up analysis after 3 years,MP+ bortezomibhas ahighly sig-
niﬁcant impact on improved OS (HR, 0.653; P b .001), with an associated
35% reduction in risk of death. Median OS has still not been reached at the
time of publication in the bortezomib group, versus 43.1 months for the
control arm, with 109 (32%) and 148 (44%) patients having died, despite
signiﬁcant crossover. This conﬁrmed survival advantage represents
an important ﬁnding, because the OS beneﬁt with VMP versus MP
was seen both overall and in an analysis restricted to patients who
had received subsequent therapy, despite 50% of patients treated
with MP being rescued with bortezomib-based therapy in the re-
lapsed setting [11].
In younger patients eligible for high-dose therapy the availability of
new drugs such as thalidomide, lenalidomide and bortezomib has pro-
vided a key step in improving the results of ASCT. The combination of
bortezomib plus dexamethasone (as evaluated in the IFM 2005-01
study) showed signiﬁcantly better response rate when applied to
conventional induction therapy prior ASCT [12]. Bortezomib may be
considered for 2 years after autologous HSCT based on the HOVON-
65/GMMG-HD4 trial. In this study eight hundred and twenty-seven
newly diagnosedmyeloma patientswere randomized to receive 3 cycles
of vincristine, adriamycin, dexamethasone (VAD) or bortezomib,
adriamycin, dexamethasone (PAD) followed by autologous stem cell
transplantation and maintenance with thalidomide 50 mg daily (VAD-
arm) or bortezomib 1.3 mg/m(2) every 2 weeks (PAD-arm). Complete
response (CR), including near CR, was superior after PAD induction
(15% v 31%; P b .001) and bortezomib maintenance (34% v 49%;
P b .001). After a median follow-up of 41 months, PFS was superior
in the PAD arm (median of 28 months v 35 months; P = .002) [13].
Moreover, bortezomib before and after autologous stem cell trans-
plantation overcomes the negative prognostic impact of renal im-
pairment in newly diagnosed multiple myeloma according to
subgroup analysis [14].
Various combination therapies of bortezomib with new classes of
antimyeloma agents have shown promising results in preclinical studies
and are currently being tested with the goal of improving response.
Lenalidomide plus bortezomib and dexamethasone was investigated by
Richardson et al. and has been found to result in high response rates:
the ORRwas 98%, with 71% of patients achieving a≥VGPR and 36% of pa-
tients achieving a CR/nCR [15]. In general, VD, VTD, PAD or others are
currently recommended as initial therapy for 3 or 4 cycles followed by
stem cell harvest and ASCT. Four-drug combinations, as tested in theEVOLUTION trial with bortezomib (V), dexamethasone (D), lenalidomide
(R) or cyclophosphamide (C) as VDC, VDR and VDCR, have yielded sim-
ilar PFS and OS, but four-drug combinations induced more side ef-
fects, so that VDR and VCD were the preferred regimens for clinical
practice [16].
Together with pomalidomide, lenalidomide is a synthetic derivative
of thalidomide originally developed in the 1990s to achieve improved
potency in the absence of signiﬁcant side effects. In refractory/relapsed
myeloma the time to progression was signiﬁcantly longer in the
patients who received lenalidomide plus dexamethasone than in
thosewho received placebo plus dexamethasone (median, 11.3 months
vs. 4.7 months; P b 0.001). Overall survival was signiﬁcantly improved
in the lenalidomide group (hazard ratio for death, 0.66; P = 0.03)
[17]. Lenalidomide plus dexamethasone was superior to placebo plus
dexamethasone also in similar study published by Weber [18]. Low-
dose dexamethasone is associated with better short-term overall
survival andwith lower toxicity than high-dose dexamethasone in com-
bination with lenalidomide [19]. As ﬁrst-line treatment for patients with
newly diagnosedMM, Palumbo et al. reported thatMPR-Rwas associated
with signiﬁcantly increased progression-free survival (31 months)
compared with MPR (14 months; HR: 0.49; P b 0.001) or melphalan —
prednisone (13 months; HR: 0.40; P b 0.001) [20].
Patients invariably relapse after initial treatment strategies, so the
concept of maintenance to prolong response is important. Maintenance
therapy with alkylating agents, as well as interferon and steroids, does
not impact on OS in MM patients. Although thalidomide consolida-
tion/maintenance results in longer EFS/PFS times, particularly among
patients failing to achieve high-quality responses after ASCT, the effect
on OS is ambiguous, and many open questions remain. The shorter OS
duration observed in several studies appears to be a result of a shorter
survival time after relapse, which may be caused by different factors.
Among others the possible selection of more resistant clones should
be particularly mentioned [21,22]. The use of lenalidomide has now
provided considerate enthusiasm for this approach based upon unprec-
edented improvement in PFD post-ASCT, aswell as in patients ineligible
for myeloablative therapy [20,23,24], although this beneﬁt is not
currently associated with an improved overall survival in one study
[25]. Higher incidence of second primary malignancies (SPM) with
prolonged use of lenalidomidewas observed in initial randomized stud-
ies and risk of this complication is studied intensively. Studies on
the role of bortezomib maintenance therapy post-ASCT and in elderly
patients are ongoing, some are currently available. Mateos and col-
leagues investigated the role of maintenance therapy with bortezomib
plus prednisone (VP) vs VT in elderly patients respectively assigned
to induction with VMP and VTP. After a median of 13 month mainte-
nance, there was a trend towards a lower TTP with VP compared
with VT (1-year TTP: 71% vs 84%; P = 0.05), though no signiﬁcant
difference was found in terms of OS (89% vs 92%, respectively with
VP and VT) [26].
Despite recent treatment advances, multiple myeloma (MM)
remains an incurable disease in the majority of patients. Second-
generation proteasome inhibitors (carﬁlzomib) and immunomodulatory
agents (pomalidomide) have recently been approved. Active clinical
research based on the knowledge of novel targets is ongoing. Some of
these novel agents seem promising, such as monoclonal antibodies
(anti-CD38 — daratumumab or anti-CS1 — elotuzumab) or the histone
deacetylase (HDAC) inhibitors [27]. Other agents under investigation
are kinase inhibitors, signaling pathway inhibitors or kinesin protein
inhibitor Arry-520 [28]. With so many novel agents under investigation,
future therapy in MM will probably involve the combined use of the
already approved drugs with some of those newly discovered.Acknowledgment
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